The "John Lewicke and Michael Yakubovich Experimental Treatment Centers Act" aims to establish a framework for experimental treatment centers in New Hampshire, authorized by the Department of Health and Human Services. These centers will provide access to investigational drugs, biologics, or devices that have completed phase one clinical trials but are not yet FDA-approved. Eligible patients must receive a recommendation from their treating physician, consider alternative FDA-approved treatments, and provide informed consent. The bill also defines key terms related to experimental treatments and emphasizes the importance of promoting access to innovative healthcare.

The legislation outlines the licensing and operational requirements for these centers, including the exemption from state insurance coverage mandates, network adequacy requirements, and prior authorization procedures. It allows the commissioner to adopt rules for scientific review boards and adverse event reporting, and enables centers to apply for a research and development tax credit. Additionally, each licensed center must allocate 2 percent of its net annual profits to support access to experimental treatments for qualifying residents. A new subparagraph exempts providers operating as experimental treatment centers from obtaining a traditional health care facility license, provided they comply with the standards set forth in the bill. The act is scheduled to take effect on January 1, 2027.

Statutes affected:
Introduced: 151:2
HB1734 text: 151:2